CDKL5 Deficiency Disorder: Some Lessons Learned 20 Years After the First Description.
Twenty years of CDKL5 data show seizure control and caregiver support drive daily success more than any single drug.
01Research in Context
What this study did
The authors looked back at 20 years of CDKL5 deficiency disorder.
They pulled together seizure data, caregiver stories, and medical notes.
The goal was to see what clinicians have learned since the first case reports.
What they found
Seizures still dominate life for most families.
Caregivers say the biggest wins come from small daily supports, not big cures.
Doctors now spot the gene faster, yet treatment choices remain limited.
How this fits with other research
Evenhuis (1996) told a similar 20-year tale, but for severe problem behavior.
Both papers blame reactive systems for slow progress.
Oeseburg et al. (2011) counted how often kids with intellectual disability also have epilepsy.
Their numbers help explain why CDKL5 cases look so complex.
Tunnicliffe et al. (2011) push the same idea: look at both genes and environment when challenging behavior shows up.
Why it matters
If you serve kids with rare genetic diagnoses, treat seizures as a core part of the behavior plan.
Track triggers, share data with neurology, and teach caregivers seizure-first response.
Small routines that lower seizure load often give you the biggest behavior gains.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a quick seizure log to your ABC data sheet and review it before every session.
02At a glance
03Original abstract
Loss of function variants in the Cyclin-dependent kinase-like 5 gene (CDKL5) causes CDKL5 deficiency disorder (CDD). Most cases of CDD are due to a de novo missense or truncating variants. The CDKL5 gene was discovered in 1998 as part of the genomic mapping of the chromosome Xp22 region that led to the discovery of the serine-threonine kinases STK9. Since then, there have been significant advancements in the description of the disease in humans, the understanding of the pathophysiology, and the management of the disease. There have been many lessons learned since the initial description of the condition in humans in 2003. In this article, we will focus on pathophysiology, clinical manifestations, with particular focus on seizures because of its relevance to the medical practitioners and researchers and guidelines for management. We finalize the manuscript with the voice of the parents and caregivers, as discussed with the 2019 meeting with the Food and Drug Administration.
American journal on intellectual and developmental disabilities, 2024 · doi:10.1111/epi.17239